Saturday, December 21, 2024 12/21/2024

Development and Validation of a PBPK/PD Modeling Strategy for Ophthalmic Drug Products to Support Translation from Preclinical Species to Human

Award Number: U01FD006927
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Ocular PBPK/PD Model Extrapolation from Animal to Human – Abstract The Office of Generic Drugs (OGD) is tasked, among other things, with reviewing sponsor applications for ocular dosage forms that purport to be bioequivalent to the approved formulations for the same drug. Sponsor companies want to have high confidence that applications they submit for locally acting dosage forms thought to be bioequivalent (BE) will receive favorable reviews. Software that embodies physiologically-based pharmacokinetics (PBPK) / pharmacodynamics (PD) modeling can serve as a useful alternative to conventional BE approaches to evaluate the likelihood that a new locally acting formulation will be BE to an approved dosage form in the target patient population. Developing a state-of-the-art capability for ocular PBPK/PD software and defining strategies for interspecies translation of models requires an extensive knowledge base to serve as the scientific foundation. Talented scientists apply the knowledge base in the development of useful equations and logic suitable for software, high-level computer programming skills to encode the equations and logic into user- friendly software, and other experienced scientists to test, validate, document, and support the software for the desired application by others not involved in its development. The goal of this project is to develop and validate a PBPK/PD modeling strategy for ophthalmic drug products to support translation from preclinical species to human. This will be achieved through a combination of an exhaustive review expanding the knowledge base of preclinical and clinical PK/PD data sets and legacy models for ophthalmic products, developing mechanistic PBPK/PD models in preclinical species in the Ocular Compartmental Absorption and Transit™ (OCAT™) model within the GastroPlus® software program and extrapolating to human PBPK/PD models, and validating and documenting the resulting software for use by others. By basing the analyses on the well-established and validated OCAT™ model, which has been funded previously by the FDA and is utilized by both pharmaceutical and generic drug companies today, we will be able to focus project resources entirely on identifying knowledge gaps and new strategies to support interspecies translation for ocular drug delivery and establishing scientific and regulatory standards for supporting innovative development and performing bioequivalence assessments, rather than having to develop new code for the core program and its many support capabilities (e.g., integration, plotting, Parameter Sensitivity Analysis, Virtual BE Trial Simulations). Throughout the effort, we will maintain close contact with the FDA program manager and the Consortium for Ocular PBPK/PD Model Extrapolation that we propose to form with our collaboration partners and the FDA to ensure the team focuses on data compilation and model development activities that will result in successful completion of the specific aims within the scope of the project.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $100,000 )
2024	2024	SIMULATIONS PLUS INC	42505 10TH ST W STE 103	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	002	3	1/18/2024	SUPPLEMENT FOR EXPANSION	$100,000
2024	2024	SIMULATIONS PLUS INC	42505 10TH ST W STE 103	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	004	3	2/20/2024	SUPPLEMENT FOR EXPANSION	$0
2024	2023	SIMULATIONS PLUS INC	42505 10TH ST W STE 103	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	003	3	1/24/2024	SUPPLEMENT FOR EXPANSION	-$100,000
2024	2023	SIMULATIONS PLUS INC	42505 10TH ST W STE 103	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	000	3	11/20/2023	SUPPLEMENT FOR EXPANSION	$100,000
2024	2023	SIMULATIONS PLUS INC	42505 10TH ST W STE 103	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	001	3	1/9/2024	SUPPLEMENT FOR EXPANSION	$0
2024	2022	SIMULATIONS PLUS INC	42505 10TH ST W STE 103	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	005	3	6/7/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $100,000

Issue Date FY: 2022 ( Subtotal = $40,000 )
2022	2022	SIMULATIONS PLUS, INC.	42505, 10TH STREET WEST	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	000	3	8/19/2022	NON-COMPETING CONTINUATION	$40,000
														Subtotal = $40,000

Issue Date FY: 2021 ( Subtotal = $180,000 )
2021	2021	SIMULATIONS PLUS, INC.	42505 10TH ST W	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	000	2	8/3/2021	NON-COMPETING CONTINUATION	$180,000
														Subtotal = $180,000

Issue Date FY: 2020 ( Subtotal = $180,000 )
2020	2020	SIMULATIONS PLUS, INC.	42505 10TH ST W	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	000	1	5/18/2020	NEW	$180,000
														Subtotal = $180,000

Grand Total All Awards = $500,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development and Validation of a PBPK/PD Modeling Strategy for Ophthalmic Drug Products to Support Translation from Preclinical Species to Human

Award Number: U01FD006927

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer